In race to develop obesity drugs, Roche acquires California biotech for $2.7B
Suddenly, Eli Lilly and Co. has a new potential competitor in the lucrative market for obesity drugs. Roche AG, the health care giant based in Basel, Switzerland, says is acquiring a California-based biotech that is developing obesity drugs for $2.7 billion.... Read More